QBTS Gains on CHIPS Act Optimism, But Conversion Risks Remain

What happened

D-Wave Quantum stock has rallied after news of a proposed $100M CHIPS Act award, which the company has disclosed is conditional on issuing $100M in common shares, raising dilution concerns. While Q1'26 bookings surged to $33.4M including a $20M system sale and a $10M QCaaS deal, recognized revenue fell to just $2.9M, highlighting the persistent gap between bookings and revenue conversion. The company holds $588M in liquidity, but operating cash burn of $45M per quarter and a history of equity financing mean dilution remains an ever-present risk. The comparison to Rigetti (RGTI) is premature—QBTS must demonstrate consistent revenue recognition from its $42.4M RPO before its commercial traction narrative is validated. The pivotal catalysts are the Florida Atlantic University installation commencement by year-end and the June 1 Investor Day, where tangible gate-model deliverables are needed.

Implication

The CHIPS Act award, if finalized on dilutive terms, could compress per-share value even as liquidity is ample—treat any equity-linked funding as a red flag. The Q1'26 bookings jump is a positive leading indicator, but investors must track RPO roll-forward and deferred revenue trends each quarter to distinguish genuine conversion from lumpy system sales. The FAU Advantage2 installation must begin by Dec 31, 2026; a slip would delay revenue recognition and undermine the on-prem system thesis. The current $29 price already prices in rapid conversion, leaving little room for error—the stock could trade toward our $18 bear case if execution disappoints. Position sizing should reflect binary outcomes and the likelihood of dilution; the WAIT rating is appropriate until H2'26 data confirms revenue step-up.

Thesis delta

The new news underscores the market's focus on federal funding as a catalyst, but the DeepValue report's thesis is unchanged: the stock's fate hinges on converting booked contracts into recognized revenue without significant dilution. The CHIPS Act news adds near-term sentiment but does not alter the fundamental risk/reward—if the award comes with dilutive share issuance, it would be a negative signal. The core investment case remains binary, with the next six months providing the critical data points to decide.